Biological correlation of 18F-FDG uptake on PET in pulmonary neuroendocrine tumors

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4219-4228

  Kaira, Kyoichi ^a   Murakami, Haruyasu ^a   Endo, Masahiro ^a   Ohde, Yasuhisa ^a   Naito, Tateaki ^a   Kondo, Haruhiko ^a   Nakajima, Takashi ^a   Yamamoto, Nobuyuki ^a   Takahashi, Toshiaki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

18F FDG PET; Angiogenesis; Glucose metabolism; GLUT1; Hypoxia; Pulmonary neuroendocrine tumor

Indexed keywords

CD34 ANTIGEN; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HEXOKINASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; VASCULOTROPIN; DIAGNOSTIC AGENT; GLUCOSE TRANSPORTER 3; HIF1A PROTEIN, HUMAN; RADIOPHARMACEUTICAL AGENT; SLC2A1 PROTEIN, HUMAN; SLC2A3 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CAPILLARY DENSITY; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MALE; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY NEUROENDOCRINE TUMOR; SIGNAL TRANSDUCTION; 18F-FDG PET; ANGIOGENESIS; GLUCOSE METABOLISM; HYPOXIA; KAPLAN MEIER METHOD; METABOLISM; MICROVASCULATURE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SCINTISCANNING; TREATMENT OUTCOME; DIAGNOSTIC USE; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS;

18F-FDG PET; ANGIOGENESIS; GLUCOSE METABOLISM; GLUT1; HYPOXIA; PULMONARY NEUROENDOCRINE TUMOR;

AGED; ANTIGENS, CD34; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 3; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MICROVESSELS; MIDDLE AGED; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84891361608     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Cooper WA, Thourani VH, Gal AA, Lee RB, Mansour KA and Miller JJ: The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest 119: 14-18, 2001.
2. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Nieman L, Chrousos G, Pass H and Doppman J: Neuroendocrine tumors of the lung with proposed criteria for large cell neuroendocrine carcinoma: an ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 15: 529-553, 1991.
3. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA and Gal AA and Koss MN: Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22: 934-944, 1998.
4. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, Yokose T, Jiang SX, Inoue T, Nakagawa K, Tajima K and Nagai K: Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 24: 2470-2476, 2006.
5. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H: Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 91: 1992-2000, 2001.
6. Takei H, Asamura H, Maeshima A, Suzuki K, Kondo H, Niki T, Yamada T, Tsuchiya R and Matsuno Y: Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 214: 285-292, 2002.
7. Kaira K, Ohde Y, Endo M, Nakagawa K, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Kondo H, Nakajima T and Yamamoto N: Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors. Oncol Rep 26: 931-937, 2011.
8. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, Deneffe GJ, Nackaerts KL, Verschakelen JA, Lerut TE, Mortelmans LA, Demedts MG: Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 16: 2142-2149, 1998.
9. Brock CS, Meikle SR and Price P: Dose fluorine-18 fluorodexyglucose metabolic imaging of tumor benefit oncology? Eur J Nucl Med 24: 691-705, 1997.
10. Hoffman JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S and Coleman RE: The use of FDG-PET in differentiating infectious from malignant central nervous system lesions in patients with AIDS. J Nucl Med 33: 838, 1992.
11. 18F] FDG uptake in non-small cell lung cancer. Eur J Nucl Med 27: 1778-1785, 2000.
12. 18F- FDG PET results in lung cancer staging. J Nucl Med 45: 999-1003, 2004.
13. Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, van Tinteren H, Harris AL, van Diest PJ and van der Wall E: Differential prognostic impact of hypoxia induced and diffuse HIF-1 alpha expression in invasive breast cancer. J Clin Pathol 58: 172-177, 2005.
14. Elson DA, Ryan HE, Snow JW, Johnson R and Arbeit JM: Coordinate up-regulation of hypoxia inducible factor (HIF)-1a and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing 1. Cancer Res 60: 6189-6195, 2000.
15. Burgman P, Odonoghue JA, Humm JL and Ling CC: Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med 42: 170-175, 2001.
16. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J and: Sawyers CL: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12: 122-127, 2006.
17. 18F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms? Neoplasma 59: 257-263, 2012.
18. 18F- FDG uptake in non-small cell lung cancer. Cancer Sci 100: 753-758, 2009.
19. Ryan HE, Polni M, McNulty W, Elson D, Gassmann M, Arbeit JM and Johnson RS: Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res 60: 4010-4015, 2000.
20. 18FDG uptake in PET as an early pharmacodynamic effect in treatment of nonsmall cell lung cancer with the mTOR inhibitor everlimus. J Nucl Med 50: 1815-1819, 2009.
21. Travis WD, Rush W and Flieder DB: International Histological Classification of Tumors, Histological Typing of Lung and Pleural Tumors, 1999.
22. 18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 28: 3746-3753, 2010.
23. 18F- deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer. Eur J Cancer 43: 1392-1398, 2007.
24. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 48: 771-775, 2007.
25. Song YS, Lee WW, Chung JH, Park SY, Kim YK and Kim SE: Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer 61: 54-60, 2008.
26. Younes M, Brown RW, Stephenson M, Gondo M and Cagle PT: Over expression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80: 1046-1051, 1997.
27. Ozbudak IH, Shilo K, Tavora F, Rassaei N, Chu WS, Fukuoka J, Jen J, Travis WD and Franks TJ: Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis. Modern Pathol 22: 633-638, 2009.
28. Lee YJ, Cho A, Cho BC, Yun M, Kim SK, Chang J, Moon JW, Park IK, Choi HJ and Kim JH: High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res 15: 2426-2432, 2009.
29. Pedersen MW, Holm S, Lund EL, Højgaard L and Kristjansen PE: Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia 3: 80-87, 2001.
30. Inoannou M, Papamichali R, Kouvaras E, Mylonis I, Vageli D, Kerenidou T, Barbanis S, Daponte A, Simos G, Gourgoulianis K and Koukoulis GK: Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma. Lung 187: 321-329, 2009.